Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: Results of two randomized, double-blind, vehicle-controlled pivotal studies

Journal of Drugs in Dermatology

Volumn 12, Issue 6, 2013, Pages 650-656

  Fowler, Joseph ^a   Jackson, J Mark ^a   Moore, Angela ^b   Jarratt, Michael ^c   Jones, Terry ^d   Meadows, Kappa ^e   Steinhoff, Martin ^f   Rudisill, Diane ^g   Leoni, Matthew ^g  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b Arlington Center for Dermatology   (United States)

^c AND Inc   (United States)

^d World Tourism Network and Tourism More   (United States)

^e Education and Research Foundation   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Galderma RandD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FACE ERYTHEMA; FEMALE; FLUSHING; FOLLOW UP; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SELF EVALUATION; SIDE EFFECT; SKIN IRRITATION;

EID: 84878653940     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rosacea riddle now threatens more than 16 million Americans. Available at http://www.rosacea.org/weblog/2010/04/01/rosacea-incidence-on-rise/index.php Accessed April 1, 2010.
2. Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB, Feldman SR. Managing rosacea: A review of the use of Metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol. 2007;6:495-8.
3. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-7.
4. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69:419-23. (Pubitemid 19226109)
5. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Do Not Penalties Acad Dermatol Venerol. 2005;19:273-85. (Pubitemid 40691703)
6. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-41. (Pubitemid 39178655)
7. Wolf JE Jr. Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
8. Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719-25.
9. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R et al. Standard grading system for rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-12. (Pubitemid 38685771)
10. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M et al. Standard management options for rosacea, Part I: overview and broad spectrum of care. Cutis. 2009;84:43-7.
11. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M et al. Standard management options for rosacea, Part II: option according to subtype. Cutis. 2009;84:97-104.
12. Singer MI. Drug therapy of rosacea: a problem-directed approach. J Cutan Med Surg. 1998; 2 (Suppl. 4):20-3.
13. Powell FC. Rosacea. N Engl J Med. 2005;352:793-803.
14. Wilkin JK. Rosacea: pathophysiology and treatment. Arch Dermatol. 1994;130:359-62. (Pubitemid 24107876)
15. Del Rosso JQ. Advances in understanding and managing rosacea: part1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16-25.
16. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD et al. Clinical, cellular and molecular aspects in the pathophysiology of Rosacea. J Invest Dermatol Symp Proc. 2011;15:2-11.
17. Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:53-62.
18. 1-adrenergic receptor agonist, Oxymetazoline. Arch Dermatol. 2007;143:1369-71.
19. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989; 20:202-5. (Pubitemid 19055625)
20. Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol. 2005;53:881-4. (Pubitemid 41501387)
21. Rahman MQ, Ramaesh K, Montgomery DNI. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010;9:483-91.
22. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group. Am J Ophthalmol. 1999;127:20-6. (Pubitemid 29036611)
23. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The brimonidine study group III. Surv Ophthalmol. 1996; 41 (Suppl 1):S39-47. (Pubitemid 26422592)
24. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies. Br J Dermatol. 2012; 166(3): 633-41.
25. Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhiology 1996;34:9-13. (Pubitemid 26155374)
26. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12:225-41. (Pubitemid 28130097)
27. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847-52.